Enroll in Research > Research Search & Enroll Tool > Screening for Pancreatic Cancer in Patients with an Inherited BRCA1, BRCA2, PALB2 or ATM Mutation
Screening for Pancreatic Cancer in Patients with an Inherited BRCA1, BRCA2, PALB2 or ATM Mutation

Screening for Pancreatic Cancer in Patients with an Inherited BRCA1, BRCA2, PALB2 or ATM Mutation

Clinicaltrials.gov identifier:
NCT02478892

Prevention:
Pancreatic

Study Contact Information:

Principal investigator: 
Bryson Katona, MD
Phone: 855-216-0098
Email        


Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation

About this Study

Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic ultrasound or MRI of the abdomen.

What the Study Entails

People enrolled with the study will have annual screening for pancreatic cancer using one of two procedures: 

  • Endoscopic ultrasound (EUS) involves passing a tiny scope with an attached ultrasound probe down the esophagus to the stomach. This allows doctors to look closely at the pancreas. EUS is performed as an outpatient procedure under anesthesia. 
  • Magnetic resonance imaging (MRIis a type of imaging that uses magnetic fields to look closely at internal organs such as the pancreas.

Participants will be screened and followed for ten years. 

Note: EUSs and MRIs performed on study participants are billed to insurance, and the study does not cover the cost of these procedures.

Study Site

Pennsylvania

  • Philadelphia: Abramson Cancer Center of the University of Pennsylvania
    Contact: Bryson Katona, MD by phone 855-216-0098 or email        

 

This Study is Open To:

Men and women, age 18 years or older, are eligible if they have:

  • Inherited BRCA1, BRCA2, ATM, or PALB2 mutation
  • If no history of pancreatic ductal adenocarcinoma (PDAC) in a first or second degree relative, then age of study participant must be >= 50 years old
  • If there is a history of PDAC in a first or second degree relative, minimum age to participate in study is 10 years younger than the age of onset of the youngest relative with pancreatic cancer
This Study is Not Open To:
  • People who are pregnant